Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Melanoma 20Glioblastoma 12Neoplasms 10Breast Neoplasms 10Pancreatic Neoplasms 9Glioma 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Fallopian Tube Neoplasms 4Carcinoma 4Astrocytoma 4Oligodendroglioma 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2

Interventions

fludarabine phosphate 25Cyclophosphamide 24Peripheral Blood Stem Cell Transplantation 23Busulfan 17Tacrolimus 15Methotrexate 13Cyclosporine 13ruxolitinib 12Whole-Body Irradiation 12Mycophenolic Acid 12Antilymphocyte Serum 11Filgrastim 8Decitabine 7fludarabine 6Etoposide 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6peginterferon alfa-2a 5Radiotherapy 5Methylprednisolone 5Cytarabine 5Carboplatin 5Prednisone 4Melphalan 4Biopsy 4Aspirin 4givinostat hydrochloride 3givinostat 3bomedemstat 3anagrelide 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thrombocythemia, Essential × poly ICLC × Clear all
NCT05025488 2025-04-06

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
10 enrolled
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡